1st Oct 2010 11:26
|
For immediate release |
1 October 2010 |
ABCAM PLC
("Abcam" or "the Company")
PDMR Dealings
Cambridge, UK: Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online catalogue, has today been notified of the following transactions under the Abcam plc Share Incentive Plan ("the SIP") to the benefit of PDMRs of the company:
|
Name |
Partnership Shares purchased on 24 September 2010 at 1722.55 pence per share |
Matching Shares awarded on 24 September 2010 at 1722.55 pence per share |
Subsequent Beneficial Interest in the Company |
Subsequent percentage holding of the Company's issued share capital |
|
Mark Bushfield |
7 |
7 |
598 |
0.002% |
|
Philippe Cotrel |
7 |
7 |
404 |
0.001% |
The risk of forfeiture attached to the Matching Shares will normally be removed on the third anniversary of the award subject to continued employment and the retention of the Partnership Shares in connection with which they were awarded.
No consideration was paid by the above grantees for the award of the Matching Shares and no consideration is due on their release.
For further information please contact:
|
Abcam |
+ 44 (0) 1223 696000 |
|
Jonathan Milner, Chief Executive Officer |
|
|
Jeff Iliffe, Chief Financial Officer www.abcamplc.com |
|
|
|
|
|
Numis Securities |
+ 44 (0) 20 7260 1000 |
|
Michael Meade / Freddie Barnfield - Nominated Adviser |
|
|
James Black - Corporate Broking |
|
|
|
|
|
Buchanan Communications |
+ 44 (0) 20 7466 5000 |
|
Mark Court / Jessica Fontaine |
|
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of research-grade antibodies and related products, headquartered in Cambridge, United Kingdom, with US offices in Cambridge, Massachusetts, and San Francisco, California, and Far East offices in Tokyo and Hong Kong. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third-party products to academic and commercial users throughout the world. Product ordering is available through the Company's website www.abcam.com, where customers are also able to access up-to-date and detailed technical product data sheets. All products are sold under the Abcam brand name and the Company's vision is to build the world's largest online resource of high-quality and commercially viable antibodies. Abcam now has an online catalogue of over 66,000 products, most of which are antibodies, from over 250 suppliers and employs 270 staff.
Related Shares:
ABC.L